The Role of Serum Tumor Markers in Follow-up After Surgical Treatment of Malignant Lung Tumors.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 21 07 2021
revised: 18 08 2021
accepted: 15 08 2021
entrez: 1 10 2021
pubmed: 2 10 2021
medline: 12 10 2021
Statut: ppublish

Résumé

The aim of this study was to evaluate the utility of selected tumor markers for the detection of lung cancer recurrence during follow-up. The study group consisted of 109 patients and 109 healthy controls. The following biomarkers were selected: Carcinoembryonic antigen; cytokeratin fragment 19; neuron-specific enolase; tissue polypeptide-specific antigen; cytokeratin fragments 8, 18 and 19; insulin-like growth factor 1; pro-gastrin-releasing peptide; and 25-hydroxyvitamin D. The biomarkers were assessed individually or using a multivariate analysis. Carcinoembryonic antigen [area under the receiver operating characteristics curve (AUC)=0.6857, p<0.0001] and cytokeratin fragment 19 (AUC=0.6882, p<0.0001) proved best in detecting relapse. The multivariate model indicated insulin-like growth factor 1 (p=0.0006, AUC=0.6225) as the third most useful biomarker. The multivariate model using these three markers achieved the best AUC value of 0.7730 (p=0.0050). We demonstrated that carcinoembryonic antigen and cytokeratin fragment 19 play a key role in the detection of lung cancer recurrence. A multivariate approach can increase the effectiveness of detection.

Identifiants

pubmed: 34593462
pii: 41/10/5117
doi: 10.21873/anticanres.15328
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5117-5122

Informations de copyright

Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Josef Vodicka (J)

Department of Surgery, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic.

Martin Skala (M)

Department of Surgery, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic.

Jakub Sebek (J)

Department of Surgery, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic.

Vladislav Treska (V)

Department of Surgery, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic.

Jakub Fichtl (J)

Department of Surgery, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic.

Kristyna Prochazkova (K)

Department of Surgery, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic.

Bohuslava Vankova (B)

Department of Pathology, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic.

Martin Svaton (M)

Department of Pneumology and Phtisiology, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic; svatonm@fnplzen.cz.

Ladislav Pecen (L)

Department of Immunochemistry Diagnostics, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic.

Ondrej Topolcan (O)

Department of Immunochemistry Diagnostics, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic.

Monika Bludovska (M)

Institute of Pharmacology and Toxicology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic.

Radek Kucera (R)

Department of Immunochemistry Diagnostics, Charles University, Faculty of Medicine in Pilsen, University Hospital in Pilsen, Pilsen, Czech Republic.
Institute of Pharmacology and Toxicology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH